Psychemedics (PMDI) 10-Q14 May 242024 Q1 Quarterly reportFinancial data

Company Profile

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2024	May 10, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	1-13738
Entity Registrant Name	PSYCHEMEDICS CORPORATION
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	58-1701987
Entity Address, Address Line One	5220 Spring Valley Road
Entity Address, City or Town	Dallas
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	75254
City Area Code	800
Local Phone Number	527-7424
Title of 12(b) Security	Common stock. $0.005 par value
Trading Symbol	PMD
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		5,805,611
Entity Central Index Key	0000806517
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash	$ 1,421	$ 1,964
Accounts receivable, net of allowance for doubtful accounts of $52 at June 30, 2023, and $87 at December 31, 2022	3,883	3,687
Prepaid expenses and other current assets	870	1,136
Income tax receivable	13	18
Total Current Assets	6,187	6,805
Fixed assets, net of accumulated amortization and depreciation of $22,877 at June 30, 2023, and $21,964 at December 31, 2022	2,759	3,061
Other assets	608	632
Operating lease right-of-use assets	1,598	1,828
Total Assets	11,152	12,326
Current Liabilities:
Accounts payable	1,131	752
Accrued expenses	1,780	2,604
Equipment financing debt	230	305
Current portion of operating lease liabilities	1,043	1,048
Total Current Liabilities	4,184	4,709
Long-term portion of operating lease liabilities	687	945
Total Liabilities	4,871	5,654
Commitments and Contingencies
Shareholders' Equity:
Common stock, $0.005 par value; 50,000 shares authorized; 6,411 and 6,349 shares issued and 5,743 and 5,681 shares outstanding, respectively	32	32
Additional paid-in capital	35,426	35,129
Accumulated deficit	(17,461)	(16,773)
Less - Treasury stock, at cost, 668 shares	(10,082)	(10,082)
Accumulated other comprehensive loss	(1,634)	(1,634)
Total Shareholders' Equity	6,281	6,672
Total Liabilities and Shareholders' Equity	$ 11,152	$ 12,326

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) shares in Thousands, $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Accounts Receivable, Allowance for Credit Loss, Current	$ 58	$ 64
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	$ 23,943	$ 23,633
Common stock, par value (in dollars per share)	$ 0.005	$ 0.005
Common stock, shares authorized (in shares)	50,000	50,000
Common stock, shares issued (in shares)	6,474	6,474
Common stock, shares outstanding (in shares)	5,806	5,806
Treasury stock, shares (in shares)	668	668

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues	$ 5,357	$ 5,859
Cost of revenues	3,235	3,654
Gross profit	2,122	2,205
Operating expenses:
General & administrative	1,788	1,646
Marketing & selling	692	789
Research & development	209	298
Total operating expenses	2,689	2,733
Operating (loss) income	(567)	(528)
Other (expense) income:
Settlement	(2)	0
Other	(3)	(5)
Total other (expense) income	(5)	(5)
(Loss) income before (benefit from) provision for income taxes	(572)	(533)
(Benefit from) provision for income taxes	116	(149)
Net loss	$ (688)	$ (384)
Basic net (loss) income per share (in dollars per share)	$ (0.12)	$ (0.07)
Weighted average common shares outstanding, basic and diluted (in shares)	5,806	5,685

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock, Common [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2022	6,349		668
Balance at Dec. 31, 2022	$ 32	$ 34,275	$ (10,082)	$ (11,820)	$ (1,634)	$ 10,771
Stock compensation expense	0	177	0	0	0	177
Net (loss) income	$ 0	0	$ 0	(384)	0	(384)
Shares issued – vested (in shares)	5		0
Shares issued – vested	$ 0	0	$ 0	0	0	0
Cash dividends	$ 0	0	$ 0	(398)	0	(398)
Balance (in shares) at Mar. 31, 2023	6,354		668
Balance at Mar. 31, 2023	$ 32	34,452	$ (10,082)	(12,602)	(1,634)	10,166
Balance (in shares) at Dec. 31, 2023	6,474		668
Balance at Dec. 31, 2023	$ 32	35,129	$ (10,082)	(16,773)	(1,634)	6,672
Stock compensation expense	0	297	0	0	0	297
Net (loss) income	$ 0	0	$ 0	(688)	0	(688)
Balance (in shares) at Mar. 31, 2024	6,474		668
Balance at Mar. 31, 2024	$ 32	$ 35,426	$ (10,082)	$ (17,461)	$ (1,634)	$ 6,281

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals)	3 Months Ended
	Mar. 31, 2023 $ / shares
Common Stock, Dividends, Declared (in dollars per share)	$ 0.07

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (688)	$ (384)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization	321	479
ROU asset amortization	230	235
Deferred income taxes	0	(159)
Stock-based compensation	297	177
Changes in operating assets and liabilities:
Accounts receivable	(196)	(319)
Prepaid expenses and other current assets	266	48
Income tax receivable	5	330
Accounts payable	379	337
Operating lease liabilities	(263)	(264)
Accrued expenses	(824)	(705)
Net cash provided by (used in) operating activities	(473)	(225)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of equipment and leasehold improvements	0	(20)
Cost of internally developed software	(8)	(21)
Other assets	13	(32)
Net cash provided by (used in) investing activities	5	(73)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments of equipment financing	(75)	(72)
Net cash used in financing activities	(75)	(72)
Net decrease in cash and cash equivalents	(543)	(370)
Cash and cash equivalents, beginning of period	1,964	4,750
Cash and cash equivalents, end of period	1,421	4,380
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	4	5
Cash paid for operating leases	287	291
Right-of-use assets acquired through operating leases	$ 0	$ 86

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation	3 Months Ended
Note 1 - Basis of Presentation	Mar. 31, 2024
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Basis of Presentation The interim condensed consolidated financial statements of Psychemedics Corporation (the “Company”) presented herein, have been prepared pursuant to the rules of the Securities and Exchange Commission (“SEC”) for quarterly reports on Form 10-Q and do not include all the information and note disclosures required by accounting principles generally accepted in the United States of America. These statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2023, included in the Company's 2023 Annual Report on Form 10-K (“10-K”), as filed with the SEC. The accompanying condensed consolidated financial statements are unaudited but, in the opinion of management, include all adjustments necessary for a fair presentation of results for these interim periods. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. The condensed consolidated balance sheet as of December 31, 2023, has been derived from the Company’s annual financial statements that were audited by an independent registered public accounting firm, but does not include all the information and footnotes required for complete annual financial statements. The Company’s comprehensive (loss)/income is equal to its net (loss)/income for all periods presented. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The results of operations for the three months ended March 31, 2024, may not be indicative of the results that may be expected for the year ending December 31, 2024, or any other period. Unless the context requires otherwise, the terms “we”, “us”, “our”, or “the Company” refer to Psychemedics Corporation and its wholly-owned consolidated subsidiaries.

Note 2 - Financial Information

Note 2 - Financial Information	3 Months Ended
Note 2 - Financial Information	Mar. 31, 2024
Notes to Financial Statements
Business Description and Accounting Policies [Text Block]	2. Financial Information Liquidity and Management s Plans At March 31, 2024, our principal sources of liquidity from operations included $1.4 million of cash on hand. As of the date of this report, management currently believes that such funds, together with future operating profits, should be adequate to fund anticipated working capital requirements, including debt obligations, and capital expenditures for at least the next 12 months. However, the terms of our existing equipment financing do not provide for future borrowings, and we have no existing line of credit or other fixed source of capital reserves. Depending upon our results of operations, our future capital needs, and available marketing opportunities, we may be required to seek various financing sources to raise additional funds. Such sources could include but are not limited to, issuance of common stock or debt financing, lines of credit, equipment leasing or a strategic transaction; although there is no assurance that such financings will be available to us on terms we deem acceptable, if at all. If we are unable to maintain sufficient financial resources, our business, financial condition and results of operations would be materially adversely affected. Accounts Receivable The Company believes its allowance for credit losses related to its accounts receivable remained adequate as of March 31, 2024. We maintain an allowance for credit losses based on management’s assessment of the collectability of our customer accounts by reviewing customer payment patterns and other relevant factors. We review the adequacy of the allowance for credit losses on a quarterly basis and adjust the balance as determined necessary. Write-offs are recorded at the time a customer account is deemed uncollectable. Recent Accounting Pronouncements In November 2023, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU requires disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker, among other provisions. The ASU is effective for fiscal year periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the ASU requires retrospective application to all prior periods presented in the financial statements. We are currently evaluating the standard to determine the impact of adoption to our consolidated financial statements and disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvement to Income Tax Disclosures to enhance the transparency and decision usefulness of income tax disclosures. The ASU primarily enhances and expands both the income tax rate reconciliation disclosure and the income taxes paid disclosure. The ASU is effective for annual periods beginning after December 15, 2024 on a prospective basis. Early adoption is permitted. We are currently evaluating the standard to determine the impact of adoption to our consolidated financial statements and disclosures.

Note 4 - Stock-based Compensati

Note 4 - Stock-based Compensation	3 Months Ended
Note 4 - Stock-based Compensation	Mar. 31, 2024
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	3. Stock-Based Compensation The Company’s 2006 Incentive Plan (the “Plan”) provides for cash-based awards or the grant or issuance of stock-based awards. As of March 31, 2024, 513 thousand shares remained available for future grant under the Plan. Stock-based compensation is measured at the grant date based on the fair value of the award and is recognized as an expense over the requisite service period (generally the vesting period of the equity grant). The compensation cost charged against income is included in cost of revenues and operating expenses as follows (in thousands): Three Months Ended March 31, 2024 2023 Stock-based compensation related to: Stock option grants $ 131 $ 20 Stock unit awards 166 157 Total stock-based compensation $ 297 $ 177 There was no income tax benefit recognized in the condensed consolidated statements of operations for stock-based compensation arrangements for the three months ended March 31, 2024, and 2023. A summary of the Company’s stock option activity for the three months ended March 31, 2024, is as follows (in thousands except per share amounts and years): Weighted Average Weighted Average Remaining Aggregate Number of Exercise Price Contractual Life Intrinsic Shares Per Share (years) Value (1) Outstanding, December 31, 2023 512 $ 6.32 8.7 - Granted 105 3.40 Canceled (42 ) 15.12 Outstanding, March 31, 2024 575 5.14 9.0 - Exercisable, March 31, 2024 50 $ 15.42 3.9 - (1) Intrinsic value is calculated based on the amount by which the closing market value of the Company’s stock exceeded the exercise price of the underlying options, multiplied by the number of shares. A summary of the Company’s stock unit award (“SUA”) activity for the three months ended March 31, 2024, is as follows (in thousands except per share amounts): Number of Shares Weighted Average Grant-Date Fair Value Per Share Outstanding & Unvested, December 31, 2023 140 $ 5.23 Granted - Converted to common stock - Cancelled - Forfeited - Outstanding & Unvested, March 31, 2024 140 5.23 As of March 31, 2024, the unamortized fair value of awards relating to outstanding SUAs and options was $1.0 million, which is expected to be amortized over a weighted average period of 3.9 years.

Note 4 - Income Taxes

Note 4 - Income Taxes	3 Months Ended
Note 4 - Income Taxes	Mar. 31, 2024
Notes to Financial Statements
Income Tax Disclosure [Text Block]	4. Income Taxes Our effective tax rate for the three months ended March 31, 2024, differs from the statutory rate primarily due to a valuation allowance recorded against our U.S. federal and state deferred tax assets. We recorded a full valuation allowance on our net deferred tax assets based on an assessment of available positive and negative evidence, including being in a three-year cumulative loss position in the U.S., projections of future taxable income, and other quantitative and qualitative information. We intend to maintain a full valuation allowance on our U.S. federal and state net deferred tax assets until there is sufficient positive evidence to support the reversal of all or some portion of the valuation allowance.

Note 5 - Net Loss Per Share

Note 5 - Net Loss Per Share	3 Months Ended
Note 5 - Net Loss Per Share	Mar. 31, 2024
Notes to Financial Statements
Earnings Per Share [Text Block]	5. Net Loss Per Share Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as stock options and stock unit awards, that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive. The following potentially dilutive securities outstanding as of March 31, 2024 and 2023 have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive: March 31 2024 2023 Options 575 402 SUAs 140 222 Total 715 624

Note 6 - Commitments and Contin

Note 6 - Commitments and Contingencies	3 Months Ended
Note 6 - Commitments and Contingencies	Mar. 31, 2024
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	6. Commitments and Contingencies From time to time, the Company is a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. When the Company becomes aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. In accordance with authoritative guidance, the Company records loss contingencies in its financial statements only for matters in which losses are probable and can be reasonably estimated. The Company continuously assesses the potential liability related to the Company’s pending litigation and revises its estimates when additional information becomes available. Although it is difficult to predict the ultimate outcome of these cases, management believes, that any ultimate liability would not have a material adverse effect on the consolidated statements of operations. However, an unforeseen unfavorable development in any of these cases could have a material adverse effect on the statements of operations or cash flows in the period in which it is recorded. Developments in legal proceedings and other matters that could cause changes in the amounts previously accrued are evaluated each reporting period. Settlements As previously reported in the 10-K, as of December 31, 2023, we paid $334 thousand in connection with a previously disclosed contract dispute regarding strategic negotiations with a shipping carrier. The remaining balance of $167 thousand, due on or before December 31, 2024, is included in accrued expenses on the accompanying unaudited condensed consolidated balance sheets.

Note 7 - Operating Leases

Note 7 - Operating Leases	3 Months Ended
Note 7 - Operating Leases	Mar. 31, 2024
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	7. Operating Leases The Company has five operating leases for office and laboratory space used to conduct business. The exercise of lease renewal options is at our discretion. There is one lease which contains renewal options to extend the lease terms included in our Right-Of-Use (“ROU”) assets and lease liabilities as they are reasonably certain of exercise. The Company regularly evaluates the renewal options and when they are reasonably certain of exercise. As most of the Company’s leases do not provide an implicit rate, the Company uses the incremental borrowing rate based on the information available at the lease commencement date in determining the net present value of the lease payments. As of March 31, 2024, the Company recognized a Right-Of-Use (“ROU”) asset of $1.6 million and an operating lease liability of $1.7 million based on the net present value of the minimum lease payments. The weighted average discount rate used for leases as of March 31, 2024, is 3.9%. The weighted average lease term as of March 31, 2024, is 2.9 years. The operating lease expense for the three months ended March 31, 2024, was $248 thousand.

Note 8 - Debt

Note 8 - Debt	3 Months Ended
Note 8 - Debt	Mar. 31, 2024
Notes to Financial Statements
Debt Disclosure [Text Block]	8. Debt On March 20, 2014, the Company entered into an equipment financing arrangement (“Loan Agreement”) with Ban c The weighted average interest rate on outstanding debt under the Loan Agreement was 3.8% for the three ended March 31, 2024. The interest expense was $4 thousand for the three months ended March 31, 2024. We were not in compliance with the fixed charge coverage ratio as of March 31, 2024. Subsequent to March 31, 2024, we received a waiver from the lender.

Note 9 - Revenue

Note 9 - Revenue	3 Months Ended
Note 9 - Revenue	Mar. 31, 2024
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	9. Revenue The table below disaggregates our external revenue by major source (in thousands): Three Months Ended March 31, 2024 2023 Testing $ 4,540 $ 4,938 Shipping/Collection (hair) 785 898 Other 32 23 Total Revenue $ 5,357 $ 5,859

Note 10 - Significant Customers

Note 10 - Significant Customers	3 Months Ended
Note 10 - Significant Customers	Mar. 31, 2024
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	10. Significant Customers The Company had no two

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
Significant Accounting Policies (Policies)	Mar. 31, 2024
Accounting Policies [Abstract]
Liquidity and Management's Plan [Policy Text Block]	Liquidity and Management s Plans At March 31, 2024, our principal sources of liquidity from operations included $1.4 million of cash on hand. As of the date of this report, management currently believes that such funds, together with future operating profits, should be adequate to fund anticipated working capital requirements, including debt obligations, and capital expenditures for at least the next 12 months. However, the terms of our existing equipment financing do not provide for future borrowings, and we have no existing line of credit or other fixed source of capital reserves. Depending upon our results of operations, our future capital needs, and available marketing opportunities, we may be required to seek various financing sources to raise additional funds. Such sources could include but are not limited to, issuance of common stock or debt financing, lines of credit, equipment leasing or a strategic transaction; although there is no assurance that such financings will be available to us on terms we deem acceptable, if at all. If we are unable to maintain sufficient financial resources, our business, financial condition and results of operations would be materially adversely affected.
Accounts Receivable [Policy Text Block]	Accounts Receivable The Company believes its allowance for credit losses related to its accounts receivable remained adequate as of March 31, 2024. We maintain an allowance for credit losses based on management’s assessment of the collectability of our customer accounts by reviewing customer payment patterns and other relevant factors. We review the adequacy of the allowance for credit losses on a quarterly basis and adjust the balance as determined necessary. Write-offs are recorded at the time a customer account is deemed uncollectable.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In November 2023, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU requires disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker, among other provisions. The ASU is effective for fiscal year periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the ASU requires retrospective application to all prior periods presented in the financial statements. We are currently evaluating the standard to determine the impact of adoption to our consolidated financial statements and disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvement to Income Tax Disclosures to enhance the transparency and decision usefulness of income tax disclosures. The ASU primarily enhances and expands both the income tax rate reconciliation disclosure and the income taxes paid disclosure. The ASU is effective for annual periods beginning after December 15, 2024 on a prospective basis. Early adoption is permitted. We are currently evaluating the standard to determine the impact of adoption to our consolidated financial statements and disclosures.

Note 4 - Stock-based Compensa_2

Note 4 - Stock-based Compensation (Tables)	3 Months Ended
Note 4 - Stock-based Compensation (Tables)	Mar. 31, 2024
Notes Tables
Share-Based Payment Arrangement, Cost by Plan [Table Text Block]	Three Months Ended March 31, 2024 2023 Stock-based compensation related to: Stock option grants $ 131 $ 20 Stock unit awards 166 157 Total stock-based compensation $ 297 $ 177
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Weighted Average Weighted Average Remaining Aggregate Number of Exercise Price Contractual Life Intrinsic Shares Per Share (years) Value (1) Outstanding, December 31, 2023 512 $ 6.32 8.7 - Granted 105 3.40 Canceled (42 ) 15.12 Outstanding, March 31, 2024 575 5.14 9.0 - Exercisable, March 31, 2024 50 $ 15.42 3.9 -
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Number of Shares Weighted Average Grant-Date Fair Value Per Share Outstanding & Unvested, December 31, 2023 140 $ 5.23 Granted - Converted to common stock - Cancelled - Forfeited - Outstanding & Unvested, March 31, 2024 140 5.23

Note 5 - Net Loss Per Share (Ta

Note 5 - Net Loss Per Share (Tables)	3 Months Ended
Note 5 - Net Loss Per Share (Tables)	Mar. 31, 2024
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	March 31 2024 2023 Options 575 402 SUAs 140 222 Total 715 624

Note 9 - Revenue (Tables)

Note 9 - Revenue (Tables)	3 Months Ended
Note 9 - Revenue (Tables)	Mar. 31, 2024
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended March 31, 2024 2023 Testing $ 4,540 $ 4,938 Shipping/Collection (hair) 785 898 Other 32 23 Total Revenue $ 5,357 $ 5,859

Note 2 - Financial Information

Note 2 - Financial Information (Details Textual) $ in Millions	Mar. 31, 2024 USD ($)
Cash	$ 1.4

Note 4 - Stock-based Compensa_3

Note 4 - Stock-based Compensation (Details Textual) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($) shares
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	3 years 10 months 24 days
Incentive Plan 2006 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) \| shares	513
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total \| $	$ 1

Note 4 - Stock-based Compensa_4

Note 4 - Stock-based Compensation - Compensation Cost (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-based compensation	$ 297	$ 177
Share-Based Payment Arrangement, Option [Member]
Share-based compensation	131	20
Stock Unit Awards [Member]
Share-based compensation	$ 166	$ 157

Note 4 - Stock-based Compensa_5

Note 4 - Stock-based Compensation - Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		3 Months Ended	12 Months Ended
		Mar. 31, 2024	Dec. 31, 2023
Outstanding (in shares)		512
Outstanding, weighted average exercise price (in dollars per share)		$ 6.32
Outstanding, weighted average remaining contractual life (Year)			8 years 8 months 12 days
Outstanding, aggregate intrinsic value	[1]	$ 0	$ 0
Granted, shares (in shares)		105
Granted, weighted average exercise price per share (in dollars per share)		$ 3.4
Canceled, shares (in shares)		(42)
Canceled, weighted average exercise price per share (in dollars per share)		$ 15.12
Outstanding, shares (in shares)		575	512
Outstanding, weighted average exercise price per share (in dollars per share)		$ 5.14	$ 6.32
Exercisable, shares (in shares)		50
Exercisable, weighted average exercise price per share (in dollars per share)		$ 15.42
Exercisable, weighted average remaining contractual life (Year)		3 years 10 months 24 days
Exercisable, aggregate intrinsic value	[1]	$ 0

[1]Intrinsic value is calculated based on the amount by which the closing market value of the Company’s stock exceeded the exercise price of the underlying options, multiplied by the number of shares.

Note 4 - Stock-based Compensa_6

Note 4 - Stock-based Compensation - Nonvested Award Activity (Details) - Stock Unit Award [Member] shares in Thousands	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Outstanding & Unvested at beginning of period (in shares)	140
Outstanding & Unvested, beginning of period, weighted average price per share (in dollars per share) \| $ / shares	$ 5.23
Granted (in shares)	0
Converted to common stock (in shares)	0
Cancelled (in shares)	0
Forfeited (in shares)	0
Outstanding & Unvested at end of period (in shares)	140
Outstanding & Unvested, end of period, weighted average price per share (in dollars per share) \| $ / shares	$ 5.23

Note 5 - Net Loss Per Share - A

Note 5 - Net Loss Per Share - Anti-dilutive Securities (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Anti-dilutive securites (in shares)	715	624
Share-Based Payment Arrangement, Option [Member]
Anti-dilutive securites (in shares)	575	402
Stock Unit Awards [Member]
Anti-dilutive securites (in shares)	140	222

Note 6 - Commitments and Cont_2

Note 6 - Commitments and Contingencies (Details Textual) - Negotiations With Shipping Carrier [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Payments for Legal Settlements		$ 334
Forecast [Member]
Payments for Legal Settlements	$ 167

Note 7 - Operating Leases (Deta

Note 7 - Operating Leases (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Operating Lease, Right-of-Use Asset	$ 1,598	$ 1,828
Operating Lease, Liability, Total	$ 1,700
Operating Lease, Weighted Average Discount Rate, Percent	3.90%
Operating Lease, Weighted Average Remaining Lease Term (Year)	2 years 10 months 24 days
Operating Lease, Expense	$ 248

Note 8 - Debt (Details Textual)

Note 8 - Debt (Details Textual) - Line of Credit [Member] - Equipment Loan Arrangement [Member] - Banc of America Leasing and Capital [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($)
Long-Term Debt, Weighted Average Interest Rate, over Time	3.80%
Interest Expense	$ 4

Note 9 - Revenue - Revenue by M

Note 9 - Revenue - Revenue by Major Source (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues	$ 5,357	$ 5,859
Testing [Member]
Revenues	4,540	4,938
Shipping/Collection (Hair) [Member]
Revenues	785	898
Other Revenue [Member]
Revenues	$ 32	$ 23

Note 10 - Significant Custome_2

Note 10 - Significant Customers (Details Textual) - Customer Concentration Risk [Member]	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue Benchmark [Member]
Number of Major Customers	0
Accounts Receivable [Member]
Number of Major Customers		2
Accounts Receivable [Member] \| Customer One [Member]
Concentration Risk, Percentage	31%	16%
Accounts Receivable [Member] \| Customer Two [Member]
Concentration Risk, Percentage	17%